On Jan. 13, 2021, Alexion announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRISﾮ (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation.

This decision was based on the recommendation of an independent data monitoring committee (IDMC), following their review of data from a pre-specified interim analysis.